

ASX RELEASE

27 DECEMBER 2017

KAZIA THERAPEUTICS LIMITED AND NOXOPHARM LIMITED

Sydney, 27 December 2017 – Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) and Noxopharm Limited (ASX: NOX) are pleased to announce the creation of a collaboration to support the future development of the Noxopharm lead program, NOX66.

Under the terms of the collaboration, Kazia will provide certain technical information and related proprietary information that is expected to assist and expedite the successful development of NOX66. In return, Kazia has agreed to take a small equity interest in Noxopharm, which will help to align the future interests of both companies.

Kazia CEO, Dr James Garner, commented, “we are delighted to facilitate the future success of NOX66, and we look forward to assisting and following the progress of the program with keen interest.”

Noxopharm CEO, Dr Graham Kelly, commented, “the collaboration with Kazia helps to ensure that the major clinical program planned in 2018 for NOX66 will proceed smoothly and with certainty. We look forward to providing our shareholders with data as the various clinical studies progress.”

[ENDS]

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates and a preclinical discovery program, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer. Licensed from Genentech in late 2016, GDC-0084 is due to enter a phase II clinical trial in early 2018. Initial data is expected in late calendar 2018, and the study is expected to complete in 2021.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data is expected in the first half of calendar 2018.